Following the undertaking of a new task by the National Agency for Medicines and Medical Devices (NAMMD) in 2015, the Agency has managed the e-mail address established on request by the Ministry of Health.
In that respect, in its 2015report, the European Medicines Agency (EMA) provides a review of initiatives undertaken by the institution coordinating the EU network of competent authorities to prevent shortages of medicines supplied to the public, posing significant risk to public health. At the same time, generated by multiple causes (manufacturing problems, medicine pricing policies, parallel export etc.), there has been an aggravating shortage tendency over the past 10 years, globally and the more so in the EU, with potentially negative impact on the healthcare of European patients.
In full agreement with the EMA, the NAMMD states that such circumstances require effective collaboration among the various stakeholders and regulators, good communication among manufacturers, distributors and authorities. This is the perspective the NAMMD has maintained in its various working meetings with representatives of market authorisation holders, manufacturers, wholesalers and patient associations.

To notify shortages, please message to